Rosiglitazone and cardiovascular risk.

  title={Rosiglitazone and cardiovascular risk.},
  author={Sanjay Kaul and George A. Diamond},
  journal={Current atherosclerosis reports},
  volume={10 5},
A meta-analysis of 42 clinical trials suggested that rosiglitazone, a widely used thiazolidinedione, was associated with a 43% greater risk of myocardial infarction (P = 0.03) and a 64% greater risk of cardiovascular death (P = 0.06). However, a number of criticisms have been raised that potentially undermine the conclusions of this analysis. In this article, we point out some of these limitations, summarize the currently available evidence concerning rosiglitazone and cardiovascular risk… CONTINUE READING

From This Paper

Topics from this paper.
21 Citations
0 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 21 extracted citations

Similar Papers

Loading similar papers…